SCHEMBL6461628

SCHEMBL6461628

CN1CCN(C(=O)c2cccc(-c3sc(C(C)(C)c4c(Cl)cc(-n5ncc(=O)[nH]c5=O)cc4Cl)nc3-c3ccccc3Cl)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.38
THRB P10828 5/20 0.38
PARP1 P09874 2/20 0.37
THRA P10827 2/20 0.36
PIK3CA P42336 3/20 0.35
MTOR P42345 3/20 0.35
PDE5A O76074 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE7A Q13946 1/20 0.35
PDE1C Q14123 1/20 0.35
PDE3A Q14432 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ABCB11 O95342 1/20 0.35
P2RX7 Q99572 1/20 0.35
BTK Q06187 1/20 0.35
PIK3CD O00329 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135587 0.89 P2RX7 (0.38) THRBTHRAABCB11P2RX7
SCHEMBL6459797 0.83 P2RX7 (0.39) THRBTHRAABCB11P2RX7
SCHEMBL6461284 0.82 P2RX7 (0.35) THRBTHRAABCB11P2RX7
SCHEMBL6462754 0.79 P2RX7 (0.41) THRBTHRAABCB11P2RX7
SCHEMBL6459898 0.79 THRB (0.39) THRBTHRAABCB11P2RX7
SCHEMBL6464512 0.78 P2RX7 (0.34) ADORA2AABCB11P2RX7BTKADORA1
SCHEMBL6461977 0.77 THRB (0.36) THRBTHRAABCB11P2RX7
SCHEMBL6454694 0.76 P2RX7 (0.40) THRBPDE5APDE1APDE1BPDE1C
SCHEMBL6462166 0.76 P2RX7 (0.38) THRBTHRAABCB11P2RX7PIK3CD
SCHEMBL6460658 0.76 THRB (0.35) THRBTHRAABCB11P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
EP-1114046-B1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-04-23 EP disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed
EP-0987265-A1 Interleukin-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST ADORA2A 2081/4885THRB 1610/4885PARP1 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.